In the last trading session, 1.13 million shares of the ARS Pharmaceuticals Inc (NASDAQ:SPRY) were traded, and its beta was 0.88. Most recently the company’s share price was $13.79, and it changed around $0.01 or 0.07% from the last close, which brings the market valuation of the company to $1.34B. SPRY currently trades at a discount to its 52-week high of $18.51, offering almost -34.23% off that amount. The share price’s 52-week low was $4.64, which indicates that the current value has risen by an impressive 66.35% since then. We note from ARS Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.63 million shares, with the 3-month average coming to 1.16 million.
ARS Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended SPRY as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. ARS Pharmaceuticals Inc is expected to report earnings per share of 0.0 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY has showed a green trend with a performance of 0.07% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 16.51 on recent trading dayincreased the stock’s daily price by 16.47%. The company’s shares are currently up 151.64% year-to-date, but still down -16.98% over the last five days. On the other hand, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is -17.52% down in the 30-day period. We can see from the shorts that 12.6 million shares have been sold at a short interest cover period of 14.25 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 37.32% from its current value. Analyst projections state that SPRY is forecast to be at a low of $18 and a high of $30.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
ARS Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 56.17 percent over the past six months and at a 12.28% annual growth rate that is well below the industry average of 16.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 100.00% in revenue this quarter, and will report a decrease of -159.09% in the next quarter. The year-over-year growth rate is expected to be 93,770.00%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 25.58M in revenue for the current quarter. 3 analysts expect ARS Pharmaceuticals Inc to make 10.36M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at ∞%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -1.44%.
SPRY Dividends
ARS Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in December.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 23.16% of ARS Pharmaceuticals Inc shares, and 68.11% of them are in the hands of institutional investors. The stock currently has a share float of 88.64%.
